Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer

Expert Rev Vaccines. 2013 Mar;12(3):263-70. doi: 10.1586/erv.13.14.

Abstract

Therapeutic vaccines are different from the well-known prophylactic vaccines in that they are designed to treat patients already suffering from a disease instead of preventing the disease in healthy individuals. Several therapeutic vaccines are today in late-stage clinical development for non-small-cell lung cancer. These vaccines use different approaches including peptides, cell lines and viral vectors, and explore different settings within the pathology. Some are given in monotherapy while others are combined with the classic therapies used with non-small-cell lung cancer. This review gives a summary of the therapeutic vaccines currently in late-stage clinical development for non-small-cell lung cancer.

Publication types

  • Review

MeSH terms

  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy, Active / methods*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Membrane Glycoproteins / administration & dosage
  • Membrane Glycoproteins / immunology
  • Membrane Glycoproteins / therapeutic use

Substances

  • Cancer Vaccines
  • Membrane Glycoproteins
  • TG4010